SPRY ARS Pharmaceuticals Inc

Price (delayed)

$11.35

Market cap

$1.1B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.52

Enterprise value

$1.04B

Silverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically ...

Highlights
ARS Pharmaceuticals's debt has decreased by 50% YoY and by 21% from the previous quarter
SPRY's EPS is up by 34% year-on-year and by 9% since the previous quarter
ARS Pharmaceuticals's quick ratio has soared by 124% YoY but it has decreased by 37% from the previous quarter
The net income has decreased by 17% YoY but it has increased by 9% QoQ
SPRY's gross profit has dropped by 99% year-on-year and by 67% since the previous quarter
SPRY's revenue has dropped by 99% year-on-year and by 67% since the previous quarter

Key stats

What are the main financial stats of SPRY
Market
Shares outstanding
96.9M
Market cap
$1.1B
Enterprise value
$1.04B
Valuations
Price to book (P/B)
4.89
Price to sales (P/S)
109,512.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
104,397.22
Earnings
Revenue
$10,000
EBIT
-$49.7M
EBITDA
-$49.63M
Free cash flow
-$53.61M
Per share
EPS
-$0.52
Free cash flow per share
-$0.56
Book value per share
$2.32
Revenue per share
$0
TBVPS
$2.36
Balance sheet
Total assets
$227.58M
Total liabilities
$3.72M
Debt
$217,000
Equity
$223.87M
Working capital
$222.53M
Liquidity
Debt to equity
0
Current ratio
60.9
Quick ratio
60.2
Net debt/EBITDA
1.12
Margins
EBITDA margin
-496,320%
Gross margin
100%
Net margin
-496,960%
Operating margin
-619,990%
Efficiency
Return on assets
-20.5%
Return on equity
-21.1%
Return on invested capital
-31.3%
Return on capital employed
-22.2%
Return on sales
-496,960%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SPRY stock price

How has the ARS Pharmaceuticals stock price performed over time
Intraday
2.16%
1 week
24.73%
1 month
24.73%
1 year
69.4%
YTD
107.12%
QTD
33.37%

Financial performance

How have ARS Pharmaceuticals's revenue and profit performed over time
Revenue
$10,000
Gross profit
$10,000
Operating income
-$62M
Net income
-$49.7M
Gross margin
100%
Net margin
-496,960%
ARS Pharmaceuticals's operating margin has shrunk by 175% QoQ
ARS Pharmaceuticals's net margin has plunged by 174% from the previous quarter
SPRY's gross profit has dropped by 99% year-on-year and by 67% since the previous quarter
SPRY's revenue has dropped by 99% year-on-year and by 67% since the previous quarter

Growth

What is ARS Pharmaceuticals's growth rate over time

Valuation

What is ARS Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.89
P/S
109,512.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
104,397.22
SPRY's EPS is up by 34% year-on-year and by 9% since the previous quarter
The price to book (P/B) is 81% higher than the last 4 quarters average of 2.7
ARS Pharmaceuticals's equity has decreased by 14% YoY and by 3% from the previous quarter
SPRY's revenue has dropped by 99% year-on-year and by 67% since the previous quarter

Efficiency

How efficient is ARS Pharmaceuticals business performance
SPRY's return on sales has dropped by 174% since the previous quarter
The company's return on assets fell by 35% YoY but it rose by 4.7% QoQ
SPRY's ROE is down by 34% YoY but it is up by 5% from the previous quarter
SPRY's return on invested capital is up by 31% year-on-year and by 8% since the previous quarter

Dividends

What is SPRY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SPRY.

Financial health

How did ARS Pharmaceuticals financials performed over time
ARS Pharmaceuticals's quick ratio has soared by 124% YoY but it has decreased by 37% from the previous quarter
The company's current ratio has surged by 124% YoY but it fell by 37% QoQ
ARS Pharmaceuticals's debt is 100% less than its equity
ARS Pharmaceuticals's debt has decreased by 50% YoY and by 21% from the previous quarter
ARS Pharmaceuticals's equity has decreased by 14% YoY and by 3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.